Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 7/20 | 0.54 |
| ▸ | MAOA | P21397 | 3/20 | 0.54 |
| ▸ | MAOB | P27338 | 3/20 | 0.54 |
| ▸ | HTR1A | P08908 | 3/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.51 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzyl Bromide SCHEMBL5708186 | 0.92 | KDM1A (0.48) | KDM1AMAOAMAOBHTR1ASLC6A2 | |
| SCHEMBL26942219 | 0.87 | KDM1A (0.61) | KDM1AMAOAMAOBHTR1ASLC6A2 | |
| SCHEMBL27488692 | 0.87 | HTR1A (0.61) | MAOAMAOBHTR1ASLC6A2SLC6A3 | |
| Formic Acid SCHEMBL28814039 | 0.81 | KDM1A (0.52) | KDM1AMAOAMAOBHTR1ASLC6A2 | |
| SCHEMBL14882717 | 0.81 | KDM1A (0.60) | KDM1AMAOAMAOBHTR1ASLC6A2 | |
| SCHEMBL1766179 | 0.80 | MAPT (0.56) | KDM1AMAOAMAOBHTR1ASLC6A2 | |
| SCHEMBL3920122 | 0.80 | HPGD (0.51) | MAOAMAOBHTR1ASLC6A2SLC6A3 | |
| SCHEMBL12842316 | 0.80 | KDM1A (0.55) | KDM1AMAOAMAOBHTR1ASLC6A2 | |
| SCHEMBL1952684 | 0.80 | HTR1A (0.63) | HTR1ASLC6A2SLC6A3ADRA1DADRA1A | |
| SCHEMBL6036178 | 0.79 | KDM1A (0.51) | KDM1AMAOAMAOBHTR1ASLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2271634-B1 | MODULATORS OF DOPAMINE NEUROTRANSMISSION | INTEGRATIVE RES LAB SWEDEN AB (SE) | 2014-02-12 | — | — | EP | disclosed |
| US-8524766-B2 | Modulators of dopamine neurotransmission | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2013-09-03 | — | — | US | disclosed |
| CN-102036976-B | Modulators of dopamine neurotransmission | NSAB AF NEUROSEARCH SWEDEN AB | 2013-05-01 | — | — | CN | disclosed |
| US-20110105461-A1 | MODULATORS OF DOPAMINE NEUROTRANSMISSION | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2011-05-05 | — | — | US | disclosed |
| US-20110104055-A1 | SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES | PROTEOTECH INC. | 2011-05-05 | — | — | US | disclosed |
| CN-102036976-A | Modulators of dopamine neurotransmission | NSAB AF NEUROSEARCH SWEDEN AB | 2011-04-27 | — | — | CN | disclosed |
| EP-2271634-A1 | MODULATORS OF DOPAMINE NEUROTRANSMISSION | NSAB, Filial af NeuroSearch Sweden AB, Sverige (DK) | 2011-01-12 | — | — | EP | disclosed |
| WO-2009133107-A1 | MODULATORS OF DOPAMINE NEUROTRANSMISSION | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2009-11-05 | — | — | WO | disclosed |
| US-7598266-B2 | Fused heterocyclic derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2009-10-06 | — | — | US | disclosed |
| US-7544707-B2 | Bicyclic derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2009-06-09 | — | — | US | disclosed |
| EP-1660428-A1 | PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2006-05-31 | — | — | EP | disclosed |
| EP-1585726-A1 | FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-10-19 | — | — | EP | disclosed |
| WO-2005019151-A1 | PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-03-03 | — | — | WO | disclosed |
| WO-2004063155-A1 | FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-07-29 | — | — | WO | disclosed |
| EP-0928791-B1 | PROCESS FOR PRODUCING 1,4-BENZODIOXANE DERIVATIVES | DAISO CO LTD (JP) | 2003-07-30 | — | — | EP | disclosed |
| US-6020503-A | Process for producing 1,4-benzodioxane derivatives | DAISO CO., LTD. (JP) | 2000-02-01 | — | — | US | disclosed |
| EP-0928791-A1 | PROCESS FOR PRODUCING 1,4-BENZODIOXANE DERIVATIVES | DAISO CO., LTD. (JP) | 1999-07-14 | — | — | EP | disclosed |
| EP-0537742-B1 | Styrene derivatives | MITSUBISHI CHEM CORP (JP) | 1996-08-21 | — | — | EP | disclosed |
| US-5514711-A | ANTICARCINOGENIC AGENTS; SIDE EFFECT REDUCTION | MITSUBISHI CHEMICAL CORPORATION (JP) | 1996-05-07 | — | — | US | disclosed |
| EP-0537742-A2 | Styrene derivatives | Mitsubishi Chemical Corporation (JP) | 1993-04-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110104055-A1 | SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES | IAPP, SNCA, BACE2 | KDM1A 3568/4885MAOA 162/4885MAOB 160/4885 |
| US-20110105461-A1 | MODULATORS OF DOPAMINE NEUROTRANSMISSION | DBH, SLC18A2, SLC6A3 | KDM1A 2057/4885MAOA 74/4885MAOB 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.